Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
Completed
National Institute on Aging (NIA)
Phase 4
2002-07-01
The primary aim of this study is to determine the safety and efficacy of quetiapine
(Seroquel) for the treatment of psychosis and/or agitation in patients with primary dementia
complicated by coexistent parkinsonism, or patients with Parkinson's disease with dementia
[PDD] who have episodes of agitation or psychosis. The secondary aim is to determine the
safety and tolerability, particularly the influence on parkinsonism, of quetiapine when used
to treat psychosis and/or agitation in patients with dementia complicated by coexistent
parkinsonism.
This study will evaluate the effectiveness of switching medications in decreasing
schizophrenia symptoms in individuals who are currently taking an antipsychotic medication
for the treatment of schizophrenia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
